A Phase 2 interventional study of Part 1: Daratumumab and Part 2: Daratumumab in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-27.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.
Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 37th largest by enrollment, is the only one that started in 2008, is one of 73 in phase 2, and was the 1st registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Australia, Belgium and 9 more countries
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
By country, each count listing its studies:
daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 84 · Phase 3 25 · Phase 4 4
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 132 interventional studies. Of the 55 that completed or were terminated, 28 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 132 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 58th largest by enrollment of the 100 interventional ones that give a count, is one of 6 that started in 2008, is one of 32 in phase 2, and was the 20th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
19 of the studies testing daratumumab in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06952478Phase 3CelltrionA Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma | 2027-03-08 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT06697483Peking University People's HospitalRisk Stratification and MRD-driven Maintenance for MM After ASCT | 2026-12-31 |
| NCT04991103University of Alabama at BirminghamMinimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | 2027-01-01 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 132 studies testing daratumumab in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
Establishment of safety profile of HuMax-CD38 when given as monotherapy in participants with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment options.
This study is conducted in two parts. In part I, participants are enrolled into cohorts at increasing dose levels. Participant safety and efficacy during part I will determine the doses used for Part II. In part II participants will be enrolled into one of two sequential treatment arms using two of the doses defined in part 1 of the study. Part II was 5 cohorts, 3 with 8 milligram per kilogram (mg/kg) and 2 with 16 mg/kg. Part I and all but the last cohort in Part II were dosed with Phase 1/ 2 drug product. The last cohort in Part II was dosed with Phase 3 drug product. Both Part I and Part II are open-label/unmasked.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Part 1: Daratumumab · Other: Methylprednisolone
Drug: Part 2: Daratumumab · Other: Methylprednisolone · Other: Dexamethasone
First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
Also known as: HuMax-CD38
In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
Also known as: HuMax-CD38
Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4. Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions.
Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.
Number of Participants With Adverse Events
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2)
Overall Response Rate
Overall response defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Per IMWG criteria, sCR: is defined as normal free light chain (FLC) ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5 % plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>= 90% reduction in serum M-protein plus urine M-protein level \< 100mg/24 hours; PR: \>= 50 % reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>= 90% or to \<200 mg/24 hours; if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.
Time frame: Up to Week 28 (for Part 1) and Week 27 (for Part 2)
Part 1: Time to Response
Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Kaplan-Meier method was used to estimate the distribution of time to response and time to best response.
Time frame: Up to Week 28
Part 2: Time to Progression (TTP)
TTP was defined as the number of days from the date of first infusion (Day 1) to the date of first record of disease progression. Disease progression (IMWG criteria): increase of 25 percent (%) from lowest response level in Serum M-component and/or (the absolute increase must be \>=0.5 g/dL); urine M-component and/or (the absolute increase must be \>=200 mg/24 hour; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase must be \>10 mg/dL); Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder. Median TTP was estimated by using the Kaplan-Meier method.
Time frame: Up to Week 27
Part 2: Duration of Response as Assessed Using the Method of Kaplan-Meier
Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the International Myeloma Working Group (IMWG) criteria.
Time frame: Up to Week 27
Part 2: Progression-Free Survival
Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first.
Time frame: Up to Week 27
Part 2: Time to Response
Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Time to VGPR (very good partial response) was defined as the time from the date of first dose of daratumumab to the date of initial documentation of VGPR response. The Kaplan-Meier method was used to estimate time to response.
Time frame: Up to Week 27
Part 2: Overall Survival
Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.
Time frame: Approximately 3 years
| Milestone | Part 1 - <4 mg/kg | Part 1 - 4 mg/kg | Part 1 - 8 mg/kg | Part 1 - 16 mg/kg | Part 1 - 24 mg/kg | Part 2 - 8 mg/kg | Part 2 - 16 mg/kg |
|---|---|---|---|---|---|---|---|
| Started | 20 | 3 | 3 | 3 | 3 | 30 | 42 |
| Completed | 0 | 0 | 0 | 1 | 1 | 4 | 14 |
| Not completed | 20 | 3 | 3 | 2 | 2 | 26 | 28 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 25 | 21 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Withdrew: Progressive disease | 17 | 2 | 3 | 2 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| participants | Part 1: Daratumumab Less Than (<) 4 mg/kg | Part 1: Daratumumab 4 mg/kg | Part 1:Daratumumab 8 mg/kg | Part 1: Daratumumab 16 mg/kg | Part 1:Daratumumab 24 mg/kg | Part 2: Daratumumab 8 mg/kg | Part 2: Daratumumab 16 mg/kg |
|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events | 19 | 3 | 3 | 3 | 3 | 30 | 41 |
Overall response defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Per IMWG criteria, sCR: is defined as normal free light chain (FLC) ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5 % plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>= 90% reduction in serum M-protein plus urine M-protein level \< 100mg/24 hours; PR: \>= 50 % reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>= 90% or to \<200 mg/24 hours; if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.
| percentage of participants | Part 1: Daratumumab 4 mg/kg | Part 1:Daratumumab 8 mg/kg | Part 1: Daratumumab 16 mg/kg | Part 1:Daratumumab 24 mg/kg | Part 2: Daratumumab 8 mg/kg | Part 2: Daratumumab 16 mg/kg |
|---|---|---|---|---|---|---|
| Overall Response Rate | 33.3 (0.8 to 90.6) | 0 (0 to 0) | 33.3 (0.8 to 90.6) | 66.7 (9.4 to 99.2) | 10.0 (2.1 to 26.5) | 35.7 (21.6 to 52.0) |
Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Kaplan-Meier method was used to estimate the distribution of time to response and time to best response.
| months | Part 1: Daratumumab 4 mg/kg | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg | Part 1:Daratumumab 24 mg/kg |
|---|---|---|---|---|
| Time to first response | NA (1.2 to NA) | NA (NA to NA) | 8.4 (NA to NA) | 1.9 (0.5 to 1.9) |
| Time to best response | NA (1.2 to NA) | NA (NA to NA) | 8.4 (NA to NA) | 1.9 (0.5 to 1.9) |
TTP was defined as the number of days from the date of first infusion (Day 1) to the date of first record of disease progression. Disease progression (IMWG criteria): increase of 25 percent (%) from lowest response level in Serum M-component and/or (the absolute increase must be \>=0.5 g/dL); urine M-component and/or (the absolute increase must be \>=200 mg/24 hour; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase must be \>10 mg/dL); Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder. Median TTP was estimated by using the Kaplan-Meier method.
| months | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Part 2: Time to Progression (TTP) | 2.4 (1.4 to 3.5) | 5.6 (4.7 to NA) |
Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the International Myeloma Working Group (IMWG) criteria.
| months | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Part 2: Duration of Response as Assessed Using the Method of Kaplan-Meier | 6.9 (6.2 to 10.6) | NA (5.6 to NA) |
Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first.
| months | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Part 2: Progression-Free Survival | 2.4 (1.4 to 3.5) | 5.6 (4.2 to 8.1) |
Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. Time to VGPR (very good partial response) was defined as the time from the date of first dose of daratumumab to the date of initial documentation of VGPR response. The Kaplan-Meier method was used to estimate time to response.
| months | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Time to first response | 1.36 ± 0.774 | 1.33 ± 0.955 |
| Time to best response | 1.36 ± 0.774 | 2.46 ± 2.800 |
| Time to VGPR or better response | — | 0.49 ± 0.000 |
Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.
| months | Daratumumab 8 mg/kg | Daratumumab 16 mg/kg |
|---|---|---|
| Part 2: Overall Survival | 18.2 (7.5 to 22.6) | 34.3 (19.9 to NA) |
Collected over Up to Week 28 (for Part 1) and approximately 2.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 - <4 mg/kg | — | 7/20 (35%) | 19/20 (95%) |
| Part 1 - 4 mg/kg | — | 0/3 (0%) | 3/3 (100%) |
| Part 1 - 8 mg/kg | — | 1/3 (33.3%) | 3/3 (100%) |
| Part 1 - 16 mg/kg | — | 2/3 (66.7%) | 3/3 (100%) |
| Part 1 - 24 mg/kg | — | 2/3 (66.7%) | 3/3 (100%) |
| Part 2 - 8 mg/kg | — | 12/30 (40%) | 30/30 (100%) |
| Part 2 - 16 mg/kg | — | 16/42 (38.1%) | 41/42 (97.6%) |
| Event | Part 1 - <4 mg/kg | Part 1 - 4 mg/kg | Part 1 - 8 mg/kg | Part 1 - 16 mg/kg | Part 1 - 24 mg/kg | Part 2 - 8 mg/kg | Part 2 - 16 mg/kg |
|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 1/20 | 0/3 | 1/3 | 1/3 | 0/3 | 1/30 | 2/42 |
| Metapneumovirus InfectionInfections and infestations | 0/20 | 0/3 | 1/3 | 0/3 | 0/3 | 0/30 | 0/42 |
| PneumoniaInfections and infestations | 0/20 | 0/3 | 0/3 | 1/3 | 0/3 | 3/30 | 3/42 |
| Urinary Tract InfectionInfections and infestations | 0/20 | 0/3 | 0/3 | 0/3 | 1/3 | 0/30 | 0/42 |
| Confusional StatePsychiatric disorders | 0/20 | 0/3 | 0/3 | 1/3 | 0/3 | 0/30 | 0/42 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 1/20 | 0/3 | 0/3 | 0/3 | 1/3 | 0/30 | 0/42 |
| Crossmatch IncompatibleInvestigations | 0/20 | 0/3 | 0/3 | 0/3 | 0/3 | 0/30 | 3/42 |
| AnaemiaBlood and lymphatic system disorders | 1/20 | 0/3 | 0/3 | 0/3 | 0/3 | 1/30 | 0/42 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/20 | 0/3 | 0/3 | 0/3 | 0/3 | 1/30 | 0/42 |
| Atrial FibrillationCardiac disorders | 1/20 | 0/3 | 0/3 | 0/3 | 0/3 | 0/30 | 0/42 |
| Event | Part 1 - <4 mg/kg | Part 1 - 4 mg/kg | Part 1 - 8 mg/kg | Part 1 - 16 mg/kg | Part 1 - 24 mg/kg | Part 2 - 8 mg/kg | Part 2 - 16 mg/kg |
|---|---|---|---|---|---|---|---|
| ProteinuriaRenal and urinary disorders | 9/20 | 1/3 | 3/3 | 1/3 | 1/3 | 0/30 | 0/42 |
| HypertensionVascular disorders | 2/20 | 0/3 | 2/3 | 0/3 | 0/3 | 0/30 | 3/42 |
| FatigueGeneral disorders | 2/20 | 0/3 | 0/3 | 0/3 | 0/3 | 13/30 | 19/42 |
| PyrexiaGeneral disorders | 7/20 | 0/3 | 0/3 | 1/3 | 0/3 | 12/30 | 9/42 |
| Rhinitis AllergicRespiratory, thoracic and mediastinal disorders | 1/20 | 0/3 | 0/3 | 0/3 | 0/3 | 12/30 | 10/42 |
| NasopharyngitisInfections and infestations | 2/20 | 0/3 | 0/3 | 0/3 | 1/3 | 7/30 | 16/42 |
| MonocytopeniaBlood and lymphatic system disorders | 2/20 | 1/3 | 0/3 | 0/3 | 0/3 | 0/30 | 0/42 |
| PalpitationsCardiac disorders | 0/20 | 1/3 | 0/3 | 0/3 | 0/3 | 0/30 | 1/42 |
| DiarrhoeaGastrointestinal disorders | 1/20 | 1/3 | 0/3 | 0/3 | 1/3 | 9/30 | 6/42 |
| Lip OedemaGastrointestinal disorders | 0/20 | 1/3 | 0/3 | 0/3 | 0/3 | 0/30 | 0/42 |
| Age, Categorical(Participants) | Part 1 - <4 mg/kg | Part 1 - 4 mg/kg | Part 1 - 8 mg/kg | Part 1 - 16 mg/kg | Part 1 - 24 mg/kg | Part 2 - 8 mg/kg | Part 2 - 16 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 2 | 2 | 3 | 2 | 21 | 22 | 63 |
| >=65 years | 9 | 1 | 1 | 0 | 1 | 9 | 20 | 41 |
| Age, Continuous(years) | Part 1 - <4 mg/kg | Part 1 - 4 mg/kg | Part 1 - 8 mg/kg | Part 1 - 16 mg/kg | Part 1 - 24 mg/kg | Part 2 - 8 mg/kg | Part 2 - 16 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 61.8 ± 9.24 | 64 ± 2 | 61.3 ± 6.11 | 53 ± 1.73 | 59 ± 9.54 | 58.6 ± 10.05 | 63.8 ± 8.27 | 61.4 ± 9 |
| Sex: Female, Male(Participants) | Part 1 - <4 mg/kg | Part 1 - 4 mg/kg | Part 1 - 8 mg/kg | Part 1 - 16 mg/kg | Part 1 - 24 mg/kg | Part 2 - 8 mg/kg | Part 2 - 16 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 7 | 2 | 0 | 0 | 0 | 9 | 15 | 33 |
| Male | 13 | 1 | 3 | 3 | 3 | 21 | 27 | 71 |
| Region of Enrollment(Participants) | Part 1 - <4 mg/kg | Part 1 - 4 mg/kg | Part 1 - 8 mg/kg | Part 1 - 16 mg/kg | Part 1 - 24 mg/kg | Part 2 - 8 mg/kg | Part 2 - 16 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Denmark | 11 | 1 | 2 | 2 | 0 | 5 | 9 | 30 |
| Netherlands | 4 | 2 | 1 | 1 | 2 | 14 | 8 | 32 |
| Sweden | 5 | 0 | 0 | 0 | 1 | 5 | 11 | 22 |
| United States | 0 | 0 | 0 | 0 | 0 | 6 | 14 | 20 |
| No. of Prior Lines of Therapy(Participants) | Part 1 - <4 mg/kg | Part 1 - 4 mg/kg | Part 1 - 8 mg/kg | Part 1 - 16 mg/kg | Part 1 - 24 mg/kg | Part 2 - 8 mg/kg | Part 2 - 16 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| <= 3 Lines | 2 | 2 | 0 | 0 | 0 | 6 | 16 | 26 |
| > 3 Lines | 18 | 1 | 3 | 3 | 3 | 24 | 26 | 78 |
| Refractory to proteasome inhibitor (PI)/immunomodulatory agent (IMiD)(Participants) | Part 1 - <4 mg/kg | Part 1 - 4 mg/kg | Part 1 - 8 mg/kg | Part 1 - 16 mg/kg | Part 1 - 24 mg/kg | Part 2 - 8 mg/kg | Part 2 - 16 mg/kg | Total |
|---|---|---|---|---|---|---|---|---|
| Both a PI and IMiD | 0 | 2 | 3 | 1 | 2 | 19 | 27 | 54 |
| PI only | 0 | 1 | 0 | 0 | 0 | 2 | 3 | 6 |
| IMiD only | 0 | 0 | 0 | 1 | 1 | 6 | 4 | 12 |
| None | 20 | 0 | 0 | 1 | 0 | 3 | 8 | 32 |
Ran from Mar 2008 to primary completion in Jan 2015, 81 months.
Results were first posted in Mar 2017, 2 years 2 months after primary completion.
Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 81 months is above that.
Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Janssen Research & Development, LLC →